Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.
about
How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.Promising therapies for treatment of nonalcoholic steatohepatitis.Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and CDocosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre TrialStatus of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis.Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.Editorial: dark chocolate may improve NAFLD and metabolic syndrome by reducing oxidative stress.Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.Editorial: non-alcoholic fatty liver disease-a pandemic in need of novel treatments and endpoints.Epigenetic reprogramming in liver fibrosis and cancer.Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease.Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
P2860
Q28074455-130878D8-648C-45FC-B592-F213EE67D3FDQ30238749-3FDD3FD6-1306-4E3A-92FF-6ED94208B77DQ30248578-A7243178-5BAB-45D8-8FCB-E069BBFD3790Q30374701-8DB7B641-4860-47FC-AEF8-AF77F750EFA5Q36225138-3EE12302-E058-4032-A69F-0FDE2B2C6BC1Q38820953-30AB2A0E-28EE-4A86-86FE-2E489520D16AQ40367115-EE208C62-3057-474D-9034-B0ABE964A9D1Q42377826-11826E97-CBC7-497C-B469-61F054090853Q46082155-5E08F4C5-3B05-4DED-8E98-0ACBD8C3991FQ46109888-C7968D93-2CA7-43CA-BDF0-AD2D841927D2Q47157566-9FA3FD04-1ADA-411B-B553-52695ED6447AQ48170286-1C4A3BE4-2D58-495F-B14F-A209CEDB8EDBQ48208576-0DA175EB-2909-4CCD-B4D4-FE456AB17770Q49813492-D19E40CF-BAEB-4F91-99F1-327302FC97D1Q58552833-F6888E21-D848-43F2-BA1D-37C1309A0E02
P2860
Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Review article: emerging anti- ...... non-alcoholic steatohepatitis.
@en
type
label
Review article: emerging anti- ...... non-alcoholic steatohepatitis.
@en
prefLabel
Review article: emerging anti- ...... non-alcoholic steatohepatitis.
@en
P2860
P356
P1476
Review article: emerging anti- ...... non-alcoholic steatohepatitis
@en
P2093
P2860
P304
P356
10.1111/APT.13620
P407
P577
2016-04-08T00:00:00Z